HER2 Biomarker Testing in Breast and Gastrointestinal Cancers: The Role of the Pathologist

Article

This publication provides a summary of key stakeholder insights on methodological limitations and analytical factors to consider pertaining to biomarker testing for HER2+ across cancer types, with particular emphasis on the role of the pathologist in the multidisciplinary management of cancer.

Related Videos
Sarah Sammons, MD
Laura Spring, MD
Laura Spring, MD
Aatur D. Singhi, MD, PhD
Rondell P. Graham, MBBS
Rachel E. Factor, MD, MS
Corey J. Langer, MD
John F. Lazar, MD
Rodolfo Bordoni, MD
Related Content
Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer

Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer

April 21st 2023
Article
Clinical Decision Making in Advanced NSCLC without Actionable Mutations

Clinical Decision Making in Advanced NSCLC without Actionable Mutations

April 21st 2023
Article
BTK Inhibitors in MCL and CLL

BTK Inhibitors in MCL and CLL

March 10th 2023
Article
Where Do ADCs Fit Into the Treatment Paradigm for Patients With NSCLC?

Where Do ADCs Fit Into the Treatment Paradigm for Patients With NSCLC?

January 25th 2023
Article
Clinical Case Scenarios: Approaches to Treatment Decisions in Non-Small Cell Lung Cancer

Clinical Case Scenarios: Approaches to Treatment Decisions in Non-Small Cell Lung Cancer

January 25th 2023
Article
Advances in the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Advances in the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

December 22nd 2022
Article